-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-408 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-408 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-408 in Alpha-1 Antitrypsin Deficiency (A1AD) Drug Details: KB-408 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:VX-634 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VX-668 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-668 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VX-668 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:VX-668 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PHP-303 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PHP-303 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PHP-303 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:PHP-303 (BAY-858501) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:ARO-AAT is under development for the treatment of liver...
-
Company Profile
Inhibrx Inc – Company Profile
Inhibrx Inc (Inhibrx) is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-101, a recombinant human AAT-Fc fusion protein candidate for the treatment of AATD (alpha-1 antitrypsin deficiency); INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating the INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1...
Add to Basket -
Product Insights
Net Present Value Model: Fazirsiran sodium
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Fazirsiran sodium Drug Details ARO-AAT is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PHP-303
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PHP-303 Drug Details PHP-303 (BAY-858501) is under development for the treatment of non-alcoholic steatohepatitis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – fazirsiran sodium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry fazirsiran sodium Drug Details ARO-AAT is under development for the treatment of liver disease...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – lonodelestat
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry lonodelestat Drug Details POL-6014 is under development for the treatment of cystic fibrosis (CF),...